Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis

Next Previous
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Exploratory Clinical Activity of NM26-2198 in Healthy Volunteers and in Adult Patients With Atopic Dermatitis

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NM26 2198 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Yellow Jersey Therapeutics

    • Most Recent Events

    • 20 Nov 2024 Status changed from recruiting to discontinued.
    • 09 Mar 2024 Planned number of patients changed from 102 to 140.
    • 09 Mar 2024 Number of treatment arms have been reduced from 8 to 2 by merging the different dosing arms into one experimental arm comprising all of them, also adding some more dose levels like-10 mg, 150 mg and 900 mg, and study design is changed from parallel to sequential.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top